Novartis Kisqali Significantly Reduced The Risk Of Recurrence By 25% Across A Broad Population Of Patients With Early Breast Cancer; Clinically Meaningful Benefit Was Consistent Across Subgroups
Portfolio Pulse from Happy Mohamed
Novartis' Kisqali has demonstrated a 25% reduction in the risk of recurrence in early breast cancer patients, according to positive primary endpoint data from the Phase III NATALEE trial. The results show a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer.
June 02, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis' Kisqali has shown a 25% reduction in the risk of recurrence in early breast cancer patients, potentially expanding the number of patients who could benefit from treatment with a CDK4/6 inhibitor.
The positive results from the Phase III NATALEE trial demonstrate that Kisqali has a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer. This could potentially more-than-double the number of patients who could benefit from treatment with a CDK4/6 inhibitor in the adjuvant setting, which would likely have a positive impact on Novartis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100